undamentalytics Newsletter
Sign in

Solventum income statement

In fiscal 2025, Solventum reported revenue of $8.32bn, up 0.9% on the year before, operating income of $2.18bn (a 26.2% margin) and net income of $1.56bn, or $8.88 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.

Income statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Revenue8,1308,1978,2548,3258,310
Gross profit4,6954,6934,5934,4514,545
Research and development767758775739725
Selling, general and administrative2,2352,2992,7823,0803,293
Operating income1,6931,6921,0362,1812,076
Income before tax1,6921,6676051,7131,696
Income tax349321127157261
Net income1,3431,3464791,5561,434
Diluted EPS$7.78$7.79$2.76$8.88$8.19
Diluted shares (average)173m173m174m175m175m
EBITDA2,2712,2531,5912,6702,401

EBITDA is operating income plus depreciation and amortisation. EPS and share counts are restated for stock splits. A dash means the company did not report the line for that period; expense lines are shown as reported, so they need not add up to the totals when a company reports other items between them.

Compare with peers

Head to head: SOLV vs VEEVSOLV vs TDOCSOLV vs TEM

More: Health Care Technology stocks compared, Health Care sector, rankings of US companies

Figures from Solventum's SEC filings (10-K and 10-Q), retrieved October 20, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Solventum.